Compass Pathways PLC

NASDAQ:CMPSUnited States

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

Contact Information

Headquarters

3Rd Floor, 1 Ashley RoadALTRINCHAM, United Kingdom WA14 2DT

Phone

---

Fax

---

Executives

Interim Independent Chairman of the Board

David Norton

Chief Executive Officer, Executive Director

Kabir Nath

Chief Financial Officer, Principal Accounting Officer

Teri Loxam

General Counsel, Chief Legal Officer

Matthew Owens

Chief Medical Officer

Guy Goodwin